GlassScriptPhysician profile
Selena Bruck
NPI 1336756956
$4,110.26
in general payments reported to CMS, 2019-2025
24 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.21 · 2022: $982 · 2023: $1,055 · 2024: $1,006 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,897 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,896.82 |
| Education | $200.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $889.39 | 2022-2025 | Wakix |
| Glaxosmithkline, LLC. | $847.07 | 2022-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $630.61 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.30 | 2022-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Baxter Healthcare | $344.15 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Floseal, Hillrom - Life 2000 Ventilation System |
| Braeburn INC. | $245.00 | 2025 | Brixadi |
| Jazz Pharmaceuticals INC. | $208.90 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $94.43 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $54.11 | 2022-2023 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $50.62 | 2022-2023 | Airduo Digihaler |
| Axsome Therapeutics, INC. | $40.24 | 2023-2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $34.01 | 2023-2025 | Glassia, Entyvio |
| Lilly USA, LLC | $33.82 | 2025 | |
| Sumitomo Pharma America, INC. | $24.20 | 2023 | Aptiom |
| Alexion Pharmaceuticals, INC. | $22.55 | 2023 | Ultomiris |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $21.57 | 2025 | Lumryz |
| Inogen, INC. | $21.52 | 2025 | |
| Phadia US INC. | $21.40 | 2023 | Immunocap |
| Eisai INC. | $20.13 | 2023 | |
| Inspire Medical Systems, INC. | $19.54 | 2025 | Inspire |
| Fisher & Paykel Healthcare INC | $18.59 | 2024 | Fisher & Paykel Healthcare |
| Covis Pharma Gmbh | $15.34 | 2022 | |
| United Therapeutics Corporation | $13.31 | 2024 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.46 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selena Bruck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.